Macquarie Group
JUNO

Macquarie Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Macquarie Group’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-9,750
Closed -$437K – 2504
2017
Q3 		$437K Buy
9,750
+1,450
+17% +$49.4K ﹤0.01% 1488
2017
Q2 		$248K Buy
+8,300
New +$205K ﹤0.01% 1398
2017
Q1 		– Sell
-28,349
Closed -$534K – 1593
2016
Q4 		$534K Sell
28,349
-64,817
-70% -$1.59M ﹤0.01% 1303
2016
Q3 		$2.8M Sell
93,166
-105,168
-53% -$3.27M 0.01% 873
2016
Q2 		$7.62M Buy
198,334
+144,684
+270% +$6.01M 0.01% 782
2016
Q1 		$2.04M Buy
+53,650
New +$1.87M ﹤0.01% 948

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Macquarie Group's JUNO Position: Q4 2017 in Review

Macquarie Group sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2017, closing a stake of 9,750 shares — an estimated $437K sold.

Macquarie Group first reported a position in JUNO in Q1 2016 and held it in 6 quarters. The position peaked at $7.62M in Q2 2016. 237 funds tracked by Wall St. Rank hold JUNO as of Q4 2017.

  • Macquarie Group reported no remaining Juno Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Macquarie Group sold 9,750 Juno Therapeutics, Inc. shares in Q4 2017, an estimated $437K.
  • Macquarie Group first reported a position in Juno Therapeutics, Inc. in Q1 2016 and held it in 6 quarters.
  • Macquarie Group's Juno Therapeutics, Inc. position peaked at $7.62M in Q2 2016.
  • 237 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2017.

Based on Macquarie Group's 13F filing for Q4 2017, filed 15 Feb 2018.